Sciomics - About Us

The Power of Proteomics: Revolutionizing Science and Healthcare

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. 

At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to improve treatment with Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling.

We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). Our microarray platform, scioDiscover, is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its reliable results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout every stage of your project. Whether you need guidance, have questions, or require full-scale project support, we are committed to ensuring your success: 

Biomarkers_in_Precision_Medicine.jpg

Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. 

Technical Expertise: Our skilled team of professionals provides unmatched proficiency in your proteomic analysis endeavors.

Customized Solutions: We provide customized solutions to meet your specific research needs.  

Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report to provide a complete picture of your medical sample.

 

Our Platform Is Used For:

• Protein Biomarker Identification and Verification

• Novel Drug Target Discovery

• Mode-of-Action Analysis

• Pathway Activity Analysis

• Disease Model Characterization, among other key applications 

 

Join us on our mission to revolutionize medicine. Together, we can reshape the future of healthcare.

News

Article | Stromal Chemokine Rewiring in B Cell Lymphoma

| March 2026 | Inflammatory reprogramming of stromal chemokine networks drives tissue disorganisation and disease progression in nodal B cell lymphoma. Sciomics supported the study with secretome profiling of human iFRC supernatant samples using the scioCD affinity proteomics platform.

Czernilofsky et al., Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma. Nature Cancer. 2026;7:538-552.  
Article | Fimepinostat Targets HDAC2 to Suppress Schwannoma Growth

| March 2026 | The HDAC inhibitor fimepinostat effectively induces apoptosis and suppresses tumor cell proliferation, highlighting its potential as a therapeutic strategy for schwannoma.
Sciomics supported the study with proteomic profiling and post-translational modification analysis of human cell samples.

Nagel et al., Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636  
Article | Parkinson’s Striatum Organoids Show Increased Inflammation Hallmarks

| February 2026 | Patient-derived striatum organoids carrying the LRRK2-G2019S mutation reveal early Parkinson’s Disease features, including neuroinflammation and altered signalling. Sciomics supported the study by analysing patient-derived striatum organoids using the scioDiscover proteomic microarray.

Barmpa et al., Parkinson’s Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation. Mov Disord. (2026), published online February 11, 2026  
Article | Fos-induced Osteosarcoma Links Cachexia-like Wasting to FGF21

| February 2026 | Fos-driven osteosarcoma induces systemic metabolic alterations and identified FGF21 as a key mediator and promising biomarker of cancer-associated cachexia. Sciomics supported the study by analysing murine serum samples using the scioDiscover proteomic microarray.

Luther et al., Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels. Cancer Metab. (2026)  
Article | Transpulmonary Pressure-Guided PEEP Improves Lung Protection

| October 2025 | In a porcine lung injury model, transpulmonary pressure–guided PEEP titration improved mechanics and reduced tidal stress. Sciomics supported the study by analysing cytokine, chemokine, and surface marker expression levels in plasma samples using the scioCD Precision Proteomics platform.

Mutschler et al., Optimizing Positive End-Expiratory Pressure in Asymmetric Acute Lung Injury in a Porcine Model: The Role of Transpulmonary Pressure. Int. J. Mol. Sci. 2025, 26, 9985  

Meet us

BIO 2026—San Diego (June 22-25, 2026)

We are excited to be part of BIO International Convention (June 22-25 in San Diego). Meet our CEO Dr. Christoph Schröder at the German Pavilion.

Swiss Biotech Day 2026—Basel (May 04-05, 2026)

Meet Dr. Ronny Schmidt, our VP Contract Research on-site at Swiss Biotech Day (May 04-05 in Basel).

bioRN Lounge (every last Tuesday of the month)

Want to meet in person? Talk to us at the bioRN Lounge, the regional monthly networking event in Heidelberg taking place every last Tuesday of the month.

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover